Armed with new phase 3 data, Bayer is preparing to file for approval of a new PET imaging agent that could accelerate the ...

Amyloid heart disease occurs when amyloid fibrils build up in the heart, making it more difficult for the heart to pump blood around the body. Eventually, this can lead to heart failure. People can ...

I 124 evuzamitide is an investigational PET radiotracer–a radioactive diagnostic imaging agent injected into the body before a PET scan to assist with visualization–being studied in patients with ...

Bayer announces positive results from phase III REVEAL study of investigational PET/CT radiotracer 124 evuzamitide: Berlin, Germany Friday, May 8, 2026, 16:00 Hrs [IST] Bayer anno ...

BridgeBio Pharma's acoramidis, marketed as BEYONTTRA, has received regulatory approval in Brazil for transthyretin amyloidosis cardiomyopathy. The approval broadens access to BEYONTTRA beyond the US, ...

For decades, antimicrobial peptides (AMPs) and amyloid-forming peptides were studied in largely separate contexts.

The Amyloidosis Program at University of Utah Health and Huntsman Cancer Institute is one of the few programs in the United States specifically designed to treat amyloidosis and provide ...

Former Edgewise and Merck leader brings more than 15 years’ experience to guide Immutrin’s clinical strategy as the Company advances towards ...

FRANKFORD (WPVI) -- Heart failure often follows heart attacks, diabetes, or high blood pressure. However, a very different cause is being identified more and more. For Elsie McGruder, the first sign ...

Cardiac amyloidosis is a myocardial disease characterized by extracellular amyloid infiltration throughout the heart. Cardiac amyloidosis has a wide spectrum of clinical manifestations but the most ...

Amyloidosis comprises a group of diseases characterized by the extracellular deposition of insoluble fibrillar proteins. This mechanism generates different clinical syndromes depending on the site and ...